This article is more than 5 years old. Information may no longer be current.

Study to evaluate elamipretide for dry AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The ReCLAIM phase 1 study evaluating the use of elamipretide for intermediate age-related macular degeneration has been initiated, according to a press release from Stealth BioTherapeutics.

The open-label study will evaluate elamipretide’s safety and tolerability through 12 weeks of treatment with daily subcutaneous injections, the release said. Patients will be age 55 years or older and have at least one eye with intermediate AMD, as well as either drusen on the retina without geographic atrophy or geographic atrophy with an unaffected central fovea.

“There are currently no FDA-approved treatment options for dry AMD, so we are eager to better understand the effect that elamipretide may have in treating these roughly 13 million patients,” Scott Cousins, MD, the trial investigator, said in the release.

Top-line data are expected in mid-2017.